Boston Scientific Closes Multibillion-Dollar BTG Deal
You may also be interested in...
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.